Nicolas Mongardon1, Alex Dyson, Mervyn Singer. 1. Bloomsbury Institute of Intensive Care Medicine, Department of Medicine, University College London, London, UK.
Abstract
PURPOSE OF REVIEW: The term 'multiorgan failure' (MOF) carries the negative connotation of major homeostatic breakdown and severe malfunction. However, this traditional paradigm may not be necessarily accurate. This review will investigate the rationale for no longer considering MOF to be simply a 'failed' pathophysiological state. RECENT FINDINGS: Multiorgan failure is characterized by a hypometabolic, immunodepressed state with clinical and biochemical evidence of decreased functioning of the body's organ systems. Notwithstanding these findings, evidence for cell death is scarce and organ recovery is frequently the rule in surviving patients without pre-existing organ disease. Decreased mitochondrial activity appears to play a key role in the processes underlying MOF, both as a victim and a player. Reduced ATP production will compromise normal metabolic functioning. To protect itself from dying, the cell may adapt by decreasing its metabolic rate, and this is clinically manifest as organ dysfunction. Mitochondrial modulation may thus represent an important therapeutic target. SUMMARY: The concept of MOF could be revisited as a transient state of metabolic shutdown analogous to hibernation. Avoiding the detrimental effects of inappropriate and counter-adaptive iatrogenic interventions is an important cornerstone of therapeutic management.
PURPOSE OF REVIEW: The term 'multiorgan failure' (MOF) carries the negative connotation of major homeostatic breakdown and severe malfunction. However, this traditional paradigm may not be necessarily accurate. This review will investigate the rationale for no longer considering MOF to be simply a 'failed' pathophysiological state. RECENT FINDINGS:Multiorgan failure is characterized by a hypometabolic, immunodepressed state with clinical and biochemical evidence of decreased functioning of the body's organ systems. Notwithstanding these findings, evidence for cell death is scarce and organ recovery is frequently the rule in surviving patients without pre-existing organ disease. Decreased mitochondrial activity appears to play a key role in the processes underlying MOF, both as a victim and a player. Reduced ATP production will compromise normal metabolic functioning. To protect itself from dying, the cell may adapt by decreasing its metabolic rate, and this is clinically manifest as organ dysfunction. Mitochondrial modulation may thus represent an important therapeutic target. SUMMARY: The concept of MOF could be revisited as a transient state of metabolic shutdown analogous to hibernation. Avoiding the detrimental effects of inappropriate and counter-adaptive iatrogenic interventions is an important cornerstone of therapeutic management.
Authors: Primrose P Freestone; Peter H Williams; Richard D Haigh; Anthony F Maggs; Christopher P Neal; Mark Lyte Journal: Shock Date: 2002-11 Impact factor: 3.454
Authors: Mark Lyte; Primrose P E Freestone; Christopher P Neal; Barton A Olson; Richard D Haigh; Roger Bayston; Peter H Williams Journal: Lancet Date: 2003-01-11 Impact factor: 79.321
Authors: Charles L Sprung; Simon L Cohen; Peter Sjokvist; Mario Baras; Hans-Henrik Bulow; Seppo Hovilehto; Didier Ledoux; Anne Lippert; Paulo Maia; Dermot Phelan; Wolfgang Schobersberger; Elisabet Wennberg; Tom Woodcock Journal: JAMA Date: 2003-08-13 Impact factor: 56.272
Authors: David Brealey; Sekhar Karyampudi; Thomas S Jacques; Marco Novelli; Ray Stidwill; Val Taylor; Ryszard T Smolenski; Mervyn Singer Journal: Am J Physiol Regul Integr Comp Physiol Date: 2003-11-06 Impact factor: 3.619
Authors: Angel López; Jose Angel Lorente; Jay Steingrub; Jan Bakker; Angela McLuckie; Sheila Willatts; Michael Brockway; Antonio Anzueto; Laurent Holzapfel; Desmond Breen; Michael S Silverman; Jukka Takala; Jill Donaldson; Carl Arneson; Geraldine Grove; Steven Grossman; Robert Grover Journal: Crit Care Med Date: 2004-01 Impact factor: 7.598
Authors: D Braga; M Barcella; F D'Avila; S Lupoli; F Tagliaferri; M H Santamaria; F A DeLano; G Baselli; G W Schmid-Schönbein; E B Kistler; F Aletti; C Barlassina Journal: Exp Biol Med (Maywood) Date: 2017-06-29
Authors: Shane M Tibby; Andrew Durward; Chong Tien Goh; Kentigern Thorburn; Kevin Morris; Mike Broadhead; Mark J Peters Journal: Intensive Care Med Date: 2012-05-15 Impact factor: 17.440